-

NIO Inc. Investor New: Robbins LLP is Investigating NIO Inc. (NIO) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating NIO Inc. (NYSE: NIO) and its officers and directors to determine whether they breached fiduciary duties and violated securities laws by pulling forward revenue and overstating its revenue growth. NIO designs, develops, manufactures, and sells smart electric vehicles.

If you would like more information about our investigation of NIO Inc.'s misconduct, click here.

What is this Case About: According to the complaint filed against NIO Inc., on June 28, 2022, Grizzly Research published a report alleging, among other things, that NIO inflated its net income by about 95% through sales to a related party, Wuhan Weineng Battery Asset Co. (“Weineng”). On this news, the Company’s American Depositary Shares (“ADSs") fell $0.59, or 2.5%, to close at $22.36 per share on June 28, 2022.

Then, on July 11, 2022, NIO announced that it formed a special committee to oversee an investigation into the allegations in the Grizzly Research report. On this news, the Company’s ADSs fell $2.03, or 8.9%, to close at $20.57 per share on July 11, 2022.

Next Steps: If you acquired shares of NIO Inc. between March 1, 2021 and July 11, 2022, you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NIO Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:NIO

Release Summary
NIO Inc. (NIO) accused of pulling forward revenue and overstating its revenue grow
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Super Micro Computer, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Super Micro Computer, Inc. (NASDAQ: SMCI) securities between April 30, 2024 and March 19, 2026. Super Micro is a technology company that designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence (“AI”), data center, and cloud solutions customers. For more information, submit a form,...

BlackRock TCP Capital Corp. Investor Alert - TCPC Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024 and January 23, 2026. BlackRock TCP is a business development company that raises funds from investors and then uses those funds to make loans to small and midsize businesses as an alternative to bank financing. For more information, submit a form, email attorney Aa...

MREO Investor Alert - Mereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025. Mereo is a biopharmaceutical company focused on the development of therapeutics for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the alleg...
Back to Newsroom